Phase 2 Study of Tarloxotinib in Patients With NSCLC Harboring EGFR Exon 20 Insertion or HER2-activating Mutations
Conditions: NSCLC, Stage IV; NSCLC Stage IIIB; NSCLC, Stage IIIC; NSCLC, Recurrent; EGFR Exon 20 Insertion Mutation; HER2-activating Mutation Intervention: Drug: tarloxotinib bromide Sponsor: Rain Therapeutics Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials